<DOC>
	<DOCNO>NCT01482442</DOCNO>
	<brief_summary>The purpose study determine whether RADIOEMBOLIZATION 90 Yttrium microspheres effective overall survival advance Hepatocellular carcinoma ( HCC ) without portal venous obstruction extrahepatic extension sorafenib standard treatment advance HCC .</brief_summary>
	<brief_title>SorAfenib Versus RADIOEMBOLIZATION Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>Background : In patient advanced hepatocellular carcinoma , sorafenib standard treatment increase median overall survival overall incidence treatment-related adverse event 80 % . There grow interest RADIOEMBOLIZAION 90 Yttrium microspheres . It involve infusion embolic microparticles glass resin impregnate isotope yttrium-90 catheter directly hepatic artery . A substantial number open-label single-group study show support evidence potential efficacy overall survival acceptable low toxicity . Trial design : multicenter , prospective , control , open label randomize trial Y90 RADIOEMBOLIZATION versus sorafenib . Participants : Adult patient 1 ) advance HCC accord BCLC staging system ( stage C ) without portal vein thrombosis 2 ) ECOG performance status 2 less 3 ) adequate haematological , renal hepatic function 4 ) liver cirrhosis Child Pugh A - B7 5 ) extrahepatic metastasis . Interventions : In sorafenib group , patient receive continuous oral treatment 400 mg sorafenib twice daily . In Y90 RADIOEMBOLIZATION group , patient first undergo angiography scintigraphy eligibility assessment ( absence acceptable lung shunt ) preconditioning ( embolization ) . RADIOEMBOLIZATION therapy infusion Y90 microspheres perform secondly . Objectives : The primary objective compare efficacy Y90 RADIOEMBOLIZATION sorafenib treatment advance hepatocellular carcinoma . Secondary objective include comparison safety profile , quality life health care cost two therapeutic group . Outcomes : The primary endpoint median overall survival time . Secondary endpoint include adverse event report accord NCI CTC , progression-free survival 6 month , response rate , general hepatic-specific quality life score , health care cost comprise MICROCOSTING Y90 RADIOEMBOLIZATION viewpoint hospital full cost strategy . Sample size : 400 participant ( 200 par arm ) . The trial 80 % power detect clinically meaningful increase median survival time 4 month sorafenib ( expect median survival time 10.7 month ) Y90 RADIOEMBOLIZATION ( expect median survival time 15 month ) two-tailed type I error risk 5 % . Randomization : 1 1 randomization stratify accord recruiting center , ECOG performance status ( score 0 vs. score 1 2 ) , presence absence macroscopic vascular invasion ( obstruction portal vein branch v none ) previous chemoembolisation failure . Randomly permute block random size use . Study duration Setting : Accrual period 24 month . Additional follow-up period : 12 month . 14 centre involve clinician ( hepatologists , hepatobiliary surgeon , oncologist ) radiologist Nuclear medicine physician site .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological cytological diagnosis meet AASLD criterion diagnosis HCC least one unidimensional lesion measurable accord RECIST criterion CTscan MRI Adult 18 year old estimate life expectancy 3 month Patient advance HCC accord BCLC staging system ( stage C ) without portal vein thrombosis , eligible surgical resection , liver transplantation radiofrequency ablation OR patient progression recurrence HCC surgical locoregional treatment eligible surgical resection , liver transplantation radiofrequency ablation OR patient chemoembolisation fail two course ( patient receive one course chemoembolisation eligible failure first round show second round impact ; patient receive two course chemoembolisation still eligible arterial network perfectly normal CT scan arterial phase ) . Failure define absence objective response two course treatment treat nodule ( objective response accord modify RECIST criterion and/or EASL criterion ) . ECOG performance status equal 1 Adequate haematological function : Hb equal 9g/100mL , absolute neutrophil count equal 1 500/mm3 , platelet count equal 50 000/mm3 Adequate renal function ; serum creatinine 150μmol/L Bilirubin equal 50 µmol/L , AST ALT uner equal 5 x ULN , INR equal 1.5 Liver cirrhosis Child Pugh A B7 write informed consent Another primary tumour , exception conventional basal cell carcinoma superficial bladder neoplasia Extrahepatic metastasis Advanced HCC previously treat Advanced liver disease ChildPugh score 7 active gastrointestinal bleeding encephalopathy ascites refractory diuretic therapy Women pregnant breast feeding Allergy contrast medium Contraindication hepatic artery catheterisation , severe peripheral vascular disease preclude catheterisation Psychiatric disorder likely impact inform consent Patient unable and/or unwilling comply treatment study instruction Patient unable swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Liver , HCC</keyword>
	<keyword>Liver , interventional procedure</keyword>
	<keyword>Liver , randomize study</keyword>
	<keyword>Liver , target therapy</keyword>
	<keyword>Liver , RADIOEMBOLIZATION</keyword>
</DOC>